CytoDyn Inc. (CYDY)

Name: CytoDyn Inc. (CYDY) annual fundamentals
Creator: TickerFacts
License: https://creativecommons.org/publicdomain/zero/1.0/

Build a valuation ↗↓ Download CSV

CIK 0001175680 · OTC · Pharmaceutical Preparations

Sector Manufacturing
Incorporated DE
Fiscal year ends May 31

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4 (ownership change) · 2026-10-20

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-08-31 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period ended	TTM to 2026-08-31	2026-05-31	2025-05-31	2024-05-31	2023-05-31	2022-05-31	2021-05-31	2020-05-31	2019-05-31	2018-05-31	2017-05-31
Revenue	n/a	n/a	n/a	n/a	$0	$266.0K	$0	n/a	n/a	n/a	n/a
Cost of Revenue	n/a	n/a	n/a	n/a	n/a	$53.0K	n/a	n/a	n/a	n/a	n/a
Gross Profit	n/a	n/a	n/a	n/a	n/a	$213.0K	n/a	n/a	n/a	n/a	n/a
R&D Expense	n/a	n/a	n/a	$7.24M	$2.63M	$27.04M	$53.40M	$52.64M	$42.49M	$38.22M	$20.21M
Operating Income	-$40.21M	-$38.58M	$9.66M	-$18.06M	-$40.58M	-$145.40M	-$104.60M	-$74.65M	-$55.85M	-$45.92M	-$27.33M
Depreciation & Amortization	$32.0K	$17.0K	$18.0K	$29.0K	$175.0K	$781.0K	$1.80M	$2.03M	$1.25M	$356.1K	$366.4K
EBITDA	-$40.17M	-$38.56M	$9.68M	-$18.03M	-$40.40M	-$144.62M	-$102.80M	-$72.61M	-$54.61M	-$45.56M	-$26.96M
Net Income	-$57.09M	-$42.70M	$3.75M	-$49.84M	-$79.82M	-$210.82M	-$176.47M	-$139.94M	-$56.19M	-$50.15M	-$25.76M
EPS (Diluted)	n/a	-$0.03	$0.00	-$0.05	-$0.10	-$0.31	-$0.30	-$0.33	n/a	n/a	n/a
Total Assets	$19.05M	$13.97M	$18.05M	$11.14M	$11.29M	$29.18M	$132.08M	$50.51M	$20.87M	$4.90M	$8.06M
Total Liabilities	$117.13M	$123.69M	$114.09M	$127.89M	$120.79M	$123.58M	$153.10M	$52.99M	$29.79M	$18.06M	$9.16M
Long-Term Debt	$35.81M	$38.34M	$45.35M	$45.02M	$45.73M	$42.22M	$64.75M	n/a	n/a	n/a	n/a
Shareholders' Equity	-$98.07M	-$109.72M	-$96.04M	-$116.76M	-$109.50M	-$94.40M	-$21.02M	-$2.48M	-$8.91M	-$13.16M	-$1.10M
Cash & Equivalents	$16.36M	$11.85M	$11.90M	$3.11M	$2.54M	$4.23M	$33.94M	$14.28M	$2.61M	$1.23M	$1.78M
Operating Cash Flow	-$22.53M	-$17.25M	-$8.77M	-$10.98M	-$25.11M	-$77.72M	-$117.57M	-$68.80M	-$50.47M	-$29.90M	-$26.73M
Capital Expenditures	n/a	n/a	n/a	n/a	n/a	n/a	$122.0K	$41.0K	$26.0K	$0	$11.1K
Free Cash Flow	n/a	n/a	n/a	n/a	n/a	n/a	-$117.69M	-$68.84M	-$50.49M	-$29.90M	-$26.74M
Shares Outstanding	1.45B	1.37B	1.25B	1.06B	918.61M	719.59M	625.68M	518.98M	329.40M	216.72M	149.47M
Weighted Average Diluted Shares	n/a	1.29B	1.24B	969.51M	836.53M	676.90M	587.59M	421.08M	n/a	n/a	n/a
EPS (Basic)	n/a	-$0.03	$0.00	-$0.05	-$0.10	-$0.31	-$0.30	-$0.33	n/a	n/a	n/a